A new peer-reviewed study published in Radiology shows that CT colonography (CTC) not only reduces colorectal cancer incidence more effectively than multitarget stool DNA (mt-sDNA) tests, but also saves costs. Simulating 10,000 individuals over 30 years, researchers found that CTC cut cancer incidence by 70–75% compared to 59% with mt-sDNA. It also proved cost-saving, while mt-sDNA, though effective, cost ~$9,000 per QALY gained.
Researchers suggest a hybrid model: use CTC every three years for small polyps, and refer only larger ones for colonoscopy—balancing prevention with economics.